Concurrent administration of triptorelin, a luteinizing hormone-releasing hormone analogue (LHRHa), and chemotherapy was associated with higher long-term probability of ovarian function compared with chemotherapy alone among premenopausal women with either hormone receptor (HR)-positive or HR-negative breast cancer, a study published in JAMA has shown.1
Because there is limited data on whether the administration of LHRHa during chemotherapy is a reliable strategy to preserve ovarian function during breast cancer chemotherapy, researchers sought to evaluate long-term results of LHRHa-induced ovarian suppression in this setting.
For the open-label, phase 3 superiority trial, researchers enrolled 281 premenopausal women with stage 1 to 3 HR-positive or -negative breast cancer. Participants were randomly assigned to receive adjuvant or neoadjuvant chemotherapy alone or chemotherapy plus triptorelin.
Results showed that at a median follow-up of 7.3 years, the 5-year cumulative incidence estimate of menstrual resumption was 72.6% (95% CI: 65.7-80.3) with triptorelin and 64.0% (95% CI: 56.2-72.8) with chemotherapy alone (HR, 1.28; 95% CI: 0.98-1.68; P=.07).
In regard to pregnancies, the 5-year cumulative incidence estimate of pregnancy was 2.1% (95% CI: 0.7-6.3) in the triptorelin arm and 1.6% (95% CI: 0.4-6.2) in the control arm (HR, 2.56; 95% CI: 0.68-9.60; P=.14).
There was also no statistically significant difference in disease-free survival for women who received triptorelin compared with those who received chemotherapy alone.
1. Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival. JAMA. 2015;314(24):2632-2640.